Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progenitor Cell Therapy (PCT), a global cell therapy services provider, has entered a manufacturing agreement with ImmunoCellular Therapeutics (IMUC ) to produce ICT-107.
Subscribe to our email newsletter
ICT-107 is a dendritic cell-based vaccine which targets multiple tumor associated antigens for glioblastoma, for its Phase II clinical trial.
Under the agreement, PCT will transfer and qualify the cGMP manufacturing process for ICT-107 for use in US based Phase II clinical trial by ImmunoCellular Therapeutics.
PCT president and chief scientific officer Robert A. Pretim said ImmunoCellular Therapeutics’ products and technologies are designed to harness the power of the immune system to improve the treatment and diagnosis of cancer.
ImmunoCellular Therapeutics president and CEO said the agreement with PCT represents a major risk mitigation step in conducting their Phase II study of ICT-107 by having two manufacturing sites.